Developer docs
API playgroundTry for free, no card

Search company profiles

Spark Biomedical

Full company profile

uuid00005us

Namestring
Spark Biomedical
Legal namestring
Spark Biomedical, Inc.
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Spark Biomedical, Inc. is a privately held, Dallas, Texas-based medical technology company founded in 2017 that develops non-invasive, wearable neurostimulation devices built on its proprietary Transcutaneous Auricular Neurostimulation (tAN) platform. The tAN architecture delivers electrical stimulation to the auricular branch of the vagus and trigeminal nerves to modulate autonomic nervous system activity without pharmaceutical intervention. The company's flagship FDA-cleared product, Sparrow Ascent, is a dual-earpiece wearable for opioid withdrawal symptom management; extensions of the same platform include Sparrow Fledgling (neonatal opioid withdrawal syndrome, FDA Breakthrough Device Designation), Sparrow Hawk (acute stress reactions in military settings, developed with Battelle under DoD funding), OhmBody (consumer-focused women's menstrual wellness sub-brand), and the Sparrow Link research platform offering a customizable Python API for academic investigators.

Spark generates revenue through three primary channels: enterprise sales to U.S. Veterans Administration institutions via formal purchase orders at $3,850 per device, direct-to-consumer transactions through the SparrowRx.com storefront, and quote-based B2B sales of research platforms to academic medical centers. The company is diversifying consumer reach through a channel partnership with menstrual care brand OVO and debuted OhmBody at CES 2026. Spark has executed more than 16 clinical trials spanning neurological health, hemostasis, pediatrics, and women's health, supported by non-dilutive grant funding totaling roughly $2.3 million from NIH, NIDA, NIAAA, DoD, and TRC4 alongside a $15 million Series A round led by WAVE Ventures with participation from Pathway to Cures (NBDF's venture philanthropy fund) closed in April 2025. With 11 to 50 employees, Spark underwent a leadership transition in May 2026 when Anja Krammer was appointed CEO to accelerate clinical and commercial scaling, while cofounder Daniel Powell moved to focus on the Neural Tourniquet product line.

Short descriptiontext

Spark Biomedical is a Dallas-based medical technology company developing FDA-cleared, non-invasive wearable neurostimulation devices using its proprietary Transcutaneous Auricular Neurostimulation (tAN) platform to treat opioid withdrawal, neonatal withdrawal, acute stress, and heavy menstrual bleeding.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDallas, United States
HQ citystring
Dallas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wearable neurostimulation devices, bioelectronic medicine, opioid withdrawal treatment, vagal nerve stimulation, non-invasive medical devices
Industry3 codes
PRIMARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYCRACAQAL
Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Wearable Neurostimulation Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Sparrow Ascent Device Sales
TypeHardware Sales
Description

Direct hardware sales of FDA-cleared Sparrow Ascent neurostimulation devices. Available through VA institutional procurement, direct consumer sales via SparrowRx.com, and healthcare providers. One-time purchase model with 90-day warranty.

sparkbiomedical.com
2Sparrow Link Research Platform
TypeHardware Sales
Description

Sale of research-grade neurostimulation equipment including pulse generators, mobile apps, hub systems, and API access to academic and institutional researchers conducting clinical trials.

sparkbiomedical.com
3SEC Exempt Offering
TypeHardware Sales
Description

Company filed SEC Notice of Exempt Offering of Securities for approximately $21.8 million offering amount with $16.2 million already sold, indicating equity financing as a funding mechanism.

sec.gov
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Pricing details2 tiers
1Sparrow Ascent - VA Institutional
ModelUnit PricingBilling cadencePay-as-you-go
Notes

VA device pricing: $3,850 per unit. SKU: 11-310-K-28. Requires formal purchase order with patient details, provider name, and VA institution information.

sparkbiomedical.com
2Sparrow Link Research Platform
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Research platform sold via quote request to academic institutions. Includes pulse generator, mobile app, hub, and Python API. Contact: michael.darrow@sparkbiomedical.com

sparkbiomedical.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1OhmBody
Description

Women’s wellness division of Spark Biomedical developing neurostimulation wearable devices for menstrual wellness. The device uses dual cranial nerve stimulation (vagus and trigeminal nerves) targeting menstrual health.

finance.yahoo.com
Core offering1 text field

Spark Biomedical develops and sells FDA-cleared, non-invasive wearable neurostimulation devices based on its proprietary Transcutaneous Auricular Neurostimulation (tAN) technology. The flagship product, Sparrow Ascent, is a wearable ear-piece device that delivers targeted electrical stimulation to the auricular branch of the vagus and trigeminal nerves to manage opioid withdrawal symptoms, with extensions into neonatal withdrawal, military acute stress, hemostasis, and women's menstrual wellness. The company also sells the Sparrow Link research platform to academic and clinical investigators, and operates a direct-to-consumer e-commerce channel at SparrowRx.com.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 84% of participants experienced mild or no withdrawal symptoms within 60 minutes of tAN therapy
+5 more records
Product overview1 text field

Spark Biomedical offers a portfolio of wearable neurostimulation products centered on its proprietary Transcutaneous Auricular Neurostimulation (tAN) technology platform. The core product is Sparrow Ascent, an FDA-cleared wearable device for opioid withdrawal management. The Sparrow Link Research Platform enables researchers to customize tAN for clinical trials across multiple indications. Sparrow Fledgling adapts the technology for neonatal opioid withdrawal syndrome (NOWS) with FDA Breakthrough Device Designation. OhmBody represents a consumer wellness sub-brand targeting women's menstrual health. Sparrow Hawk addresses acute stress reactions for military applications. The product line spans from FDA-cleared clinical products to research tools and consumer wellness applications, all utilizing the same underlying tAN neurostimulation mechanism targeting the auricular branches of the vagus and trigeminal nerves.

Product and service5 records
1Sparrow Ascent
CategoryNeurostimulation Medical Device
Description

FDA-cleared wearable neurostimulation device that uses Transcutaneous Auricular Neurostimulation (tAN) to balance the autonomic nervous system and manage opioid withdrawal symptoms. Indicated for use in patients experiencing opioid withdrawal in conjunction with standard symptomatic medication and other therapies. Features a dual earpiece design allowing alternating left/right ear use to prevent skin irritation. Sold to VA institutions at $3,850 per device and direct-to-consumer via SparrowRx.com.

2Sparrow Fledgling
CategoryNeonatal Neurostimulation Device
Description

Wearable neurostimulation device based on Sparrow Ascent technology, specifically designed for neonates experiencing Neonatal Opioid Withdrawal Syndrome (NOWS). Delivers gentle electrical stimulation to the auricular branch of the vagus and trigeminal nerves. For NICU use, offering a non-pharmacologic treatment alternative that may reduce prolonged hospital stays. Has received FDA Breakthrough Device Designation.

3Sparrow Hawk
CategoryMilitary / Defense Medical Device
Description

Non-invasive wearable neurostimulation device using tAN technology designed to address Acute Stress Reactions (ASR) in military and battlefield settings. Developed in partnership with Battelle Memorial Institute under Department of Defense funding. Aims to improve cognitive function and reduce long-term mental health risks including PTSD for military personnel and civilians.

4OhmBody
CategoryWomen's Health Consumer Wellness Device
Description

Women's wellness wearable device that uses dual cranial nerve stimulation (vagus and trigeminal nerves) for menstrual wellness. Drug-free and hormone-free, with peer-reviewed pilot research showing approximately 54-57% average reduction in menstrual blood loss and 19-20% shorter menstrual duration. Targeted at women and girls with heavy menstrual bleeding, including those with inherited bleeding disorders such as von Willebrand Disease.

5Sparrow Link Research Platform
CategoryResearch-Grade Neurostimulation Platform
Description

A non-invasive wearable neurostimulation research platform that enables research teams to customize transcutaneous auricular neurostimulation (tAN). Sold as an integrated package including the Sparrow Link Pulse Generator, Mobile App, and Hub with Python API for programmatic customization. Enables modification of stimulation output parameters including amplitude, pulse width, frequency, duty cycle, and ramping duration. Sold via quote request to academic institutions and clinical trial sponsors.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-14
Description

Lead organization for $3.4 million Phase 2 clinical trial testing Sparrow Link tAN System for reducing acute stress reaction symptoms and preventing PTSD. UNC School of Medicine partnering with US Department of Defense. Double-blind, sham-controlled trial enrolling 120 patients.

2Oregon Health & Science University
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

Academic partner for LUNA Trial Phase II clinical study evaluating tAN for heavy menstrual bleeding. Randomized, double-blind, sham-controlled decentralized study enrolling 80 participants. Part of Wellcome Leap The Missed Vital Sign program.

pharmiweb.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

Clinical partner for LUNA Trial evaluating transcutaneous auricular neurostimulation for heavy menstrual bleeding in women and girls with inherited bleeding disorders including von Willebrand disease.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

Academic collaborator for LUNA Trial women's health clinical study. Partnership with OHSU and University of Michigan funded by Wellcome Leap to advance non-pharmaceutical treatment options for heavy menstrual bleeding.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-16
Description

Lead organization for $500,000 TRC4 grant clinical trial evaluating tAN for chronic subdural hematomas. Dr. Alex Valadka leading study to develop less invasive treatment for common neurosurgical condition.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-16
Description

Collaborating institution for chronic subdural hematomas clinical trial with UT Southwestern. Partnership part of Trauma Research and Combat Casualty Care Collaborative research initiative.

7OVO
Strategic tierEmergingTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-17
Description

Menstrual care brand partnership offering OhmBody neurostimulation device through OVO's online store. OVO is a plant-based menstrual care brand expanding distribution for Spark's non-hormonal menstrual wellness device.

einpresswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-20
Description

Clinical research partner for NIH/NIAAA $305,000 grant studying tAN for alcohol withdrawal in patients with Alcohol Use Disorder. Menninger Clinic is conducting the five-day inpatient protocol study evaluating Sparrow Link device safety and efficacy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-20
Description

Academic partner for NIH/NIAAA alcohol withdrawal study. Collaborating with Menninger Clinic to evaluate neural mechanisms of tAN therapy in treating alcohol use disorder.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-12
Description

Strategic technology partner for AI algorithm development to detect and manage opioid withdrawal symptoms. Funded by $318,875 NIDA SBIR grant. Battelle contributing technical expertise for closed-loop neurostimulation development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-12
Description

Clinical partner for AI algorithm development project funded by NIDA. Hazelden Betty Ford Foundation provides addiction treatment expertise and clinical data for algorithm training to detect opioid withdrawal symptoms and cravings.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-14
Description

Long-standing partner for military neurostimulation device development. $1.15 million DoD Phase II grant for Sparrow Hawk device to address Acute Stress Reactions in military settings. Battelle developing wearable non-invasive device for battlefield conditions.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner for decentralized clinical trial operations for HMB/VWD study involving 20 subjects. Lindus Health providing clinical trial management services.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partner for platelet activity regulation study (NCT05977946). Feinstein Institutes known for vagus nerve stimulation research. Partnership leverages deep expertise in bioelectronic medicine.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile6 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Spark Biomedical

Wearable Neurostimulation Medical Devicessparkbiomedical.com

Spark Biomedical is a Dallas-based medical technology company developing FDA-cleared, non-invasive wearable neurostimulation devices using its proprietary Transcutaneous Auricular Neurostimulation (tAN) platform to treat opioid withdrawal, neonatal withdrawal, acute stress, and heavy menstrual bleeding.

What Spark Biomedical does

Spark Biomedical, Inc. is a privately held, Dallas, Texas-based medical technology company founded in 2017 that develops non-invasive, wearable neurostimulation devices built on its proprietary Transcutaneous Auricular Neurostimulation (tAN) platform. The tAN architecture delivers electrical stimulation to the auricular branch of the vagus and trigeminal nerves to modulate autonomic nervous system activity without pharmaceutical intervention. The company's flagship FDA-cleared product, Sparrow Ascent, is a dual-earpiece wearable for opioid withdrawal symptom management; extensions of the same platform include Sparrow Fledgling (neonatal opioid withdrawal syndrome, FDA Breakthrough Device Designation), Sparrow Hawk (acute stress reactions in military settings, developed with Battelle under DoD funding), OhmBody (consumer-focused women's menstrual wellness sub-brand), and the Sparrow Link research platform offering a customizable Python API for academic investigators.

Spark generates revenue through three primary channels: enterprise sales to U.S. Veterans Administration institutions via formal purchase orders at $3,850 per device, direct-to-consumer transactions through the SparrowRx.com storefront, and quote-based B2B sales of research platforms to academic medical centers. The company is diversifying consumer reach through a channel partnership with menstrual care brand OVO and debuted OhmBody at CES 2026. Spark has executed more than 16 clinical trials spanning neurological health, hemostasis, pediatrics, and women's health, supported by non-dilutive grant funding totaling roughly $2.3 million from NIH, NIDA, NIAAA, DoD, and TRC4 alongside a $15 million Series A round led by WAVE Ventures with participation from Pathway to Cures (NBDF's venture philanthropy fund) closed in April 2025. With 11 to 50 employees, Spark underwent a leadership transition in May 2026 when Anja Krammer was appointed CEO to accelerate clinical and commercial scaling, while cofounder Daniel Powell moved to focus on the Neural Tourniquet product line.

Spark Biomedical firmographics

Firmographics
Name
Spark Biomedical
Legal name
Spark Biomedical, Inc.
Website
https://sparkbiomedical.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Spark Biomedical is a Dallas-based medical technology company developing FDA-cleared, non-invasive wearable neurostimulation devices using its proprietary Transcutaneous Auricular Neurostimulation (tAN) platform to treat opioid withdrawal, neonatal withdrawal, acute stress, and heavy menstrual bleeding.
Ownership category
akta.pro rank

Spark Biomedical industry classification

Industry
Product category
Wearable Neurostimulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYCRACAQAL
Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)

Keywords

  • Wearable neurostimulation devices
  • Bioelectronic medicine
  • Opioid withdrawal treatment
  • Vagal nerve stimulation
  • Non-invasive medical devices

Where Spark Biomedical is headquartered

Location

Headquarters

HQ city
Dallas
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Spark Biomedical business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Sparrow Ascent Device Sales: Direct hardware sales of FDA-cleared Sparrow Ascent neurostimulation devices. Available through VA institutional procurement, direct consumer sales via SparrowRx.com, and healthcare providers. One-time purchase model with 90-day warranty.
  2. Sparrow Link Research Platform: Sale of research-grade neurostimulation equipment including pulse generators, mobile apps, hub systems, and API access to academic and institutional researchers conducting clinical trials.
  3. SEC Exempt Offering: Company filed SEC Notice of Exempt Offering of Securities for approximately $21.8 million offering amount with $16.2 million already sold, indicating equity financing as a funding mechanism.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goSparrow Ascent - VA Institutional
Unit PricingPay-as-you-goSparrow Link Research Platform

Go-to-market motion2 records

Distribution channels4 records

Marketing channels9 records

Spark Biomedical product offering

Product offering

Core offering

Spark Biomedical develops and sells FDA-cleared, non-invasive wearable neurostimulation devices based on its proprietary Transcutaneous Auricular Neurostimulation (tAN) technology. The flagship product, Sparrow Ascent, is a wearable ear-piece device that delivers targeted electrical stimulation to the auricular branch of the vagus and trigeminal nerves to manage opioid withdrawal symptoms, with extensions into neonatal withdrawal, military acute stress, hemostasis, and women's menstrual wellness. The company also sells the Sparrow Link research platform to academic and clinical investigators, and operates a direct-to-consumer e-commerce channel at SparrowRx.com.

Product overview

Spark Biomedical offers a portfolio of wearable neurostimulation products centered on its proprietary Transcutaneous Auricular Neurostimulation (tAN) technology platform. The core product is Sparrow Ascent, an FDA-cleared wearable device for opioid withdrawal management. The Sparrow Link Research Platform enables researchers to customize tAN for clinical trials across multiple indications. Sparrow Fledgling adapts the technology for neonatal opioid withdrawal syndrome (NOWS) with FDA Breakthrough Device Designation. OhmBody represents a consumer wellness sub-brand targeting women's menstrual health. Sparrow Hawk addresses acute stress reactions for military applications. The product line spans from FDA-cleared clinical products to research tools and consumer wellness applications, all utilizing the same underlying tAN neurostimulation mechanism targeting the auricular branches of the vagus and trigeminal nerves.

Differentiator

Problem solved

Functional benefit

Brands

  • OhmBody: Women’s wellness division of Spark Biomedical developing neurostimulation wearable devices for menstrual wellness. The device uses dual cranial nerve stimulation (vagus and trigeminal nerves) targeting menstrual health.

Products and services

  • Sparrow Ascent FDA-cleared wearable neurostimulation device that uses Transcutaneous Auricular Neurostimulation (tAN) to balance the autonomic nervous system and manage opioid withdrawal symptoms. Indicated for use in patients experiencing opioid withdrawal in conjunction with standard symptomatic medication and other therapies. Features a dual earpiece design allowing alternating left/right ear use to prevent skin irritation. Sold to VA institutions at $3,850 per device and direct-to-consumer via SparrowRx.com.
  • Sparrow Fledgling Wearable neurostimulation device based on Sparrow Ascent technology, specifically designed for neonates experiencing Neonatal Opioid Withdrawal Syndrome (NOWS). Delivers gentle electrical stimulation to the auricular branch of the vagus and trigeminal nerves. For NICU use, offering a non-pharmacologic treatment alternative that may reduce prolonged hospital stays. Has received FDA Breakthrough Device Designation.
  • Sparrow Hawk Non-invasive wearable neurostimulation device using tAN technology designed to address Acute Stress Reactions (ASR) in military and battlefield settings. Developed in partnership with Battelle Memorial Institute under Department of Defense funding. Aims to improve cognitive function and reduce long-term mental health risks including PTSD for military personnel and civilians.
  • OhmBody Women's wellness wearable device that uses dual cranial nerve stimulation (vagus and trigeminal nerves) for menstrual wellness. Drug-free and hormone-free, with peer-reviewed pilot research showing approximately 54-57% average reduction in menstrual blood loss and 19-20% shorter menstrual duration. Targeted at women and girls with heavy menstrual bleeding, including those with inherited bleeding disorders such as von Willebrand Disease.
  • Sparrow Link Research Platform A non-invasive wearable neurostimulation research platform that enables research teams to customize transcutaneous auricular neurostimulation (tAN). Sold as an integrated package including the Sparrow Link Pulse Generator, Mobile App, and Hub with Python API for programmatic customization. Enables modification of stimulation output parameters including amplitude, pulse width, frequency, duty cycle, and ramping duration. Sold via quote request to academic institutions and clinical trial sponsors.

Quantifiable outcome

  • 84% of participants experienced mild or no withdrawal symptoms within 60 minutes of tAN therapy
  • +5 more outcomes

Companies that use Spark Biomedical

Customer profile

Named customers3 records

Segments6 records

Ideal customer profiles6 records

Spark Biomedical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Spark Biomedical partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core, emerging and minor.

  • UNC Institute for Trauma RecoverycoreStrategic or Co-development Partner · 14 April 2026Lead organization for $3.4 million Phase 2 clinical trial testing Sparrow Link tAN System for reducing acute stress reaction symptoms and preventing PTSD. UNC School of Medicine partnering with US Department of Defense. Double-blind, sham-controlled trial enrolling 120 patients.
  • Oregon Health & Science UniversitycoreStrategic or Co-development Partner · 24 March 2026Academic partner for LUNA Trial Phase II clinical study evaluating tAN for heavy menstrual bleeding. Randomized, double-blind, sham-controlled decentralized study enrolling 80 participants. Part of Wellcome Leap The Missed Vital Sign program.
  • University of MichigancoreStrategic or Co-development Partner · 24 March 2026Clinical partner for LUNA Trial evaluating transcutaneous auricular neurostimulation for heavy menstrual bleeding in women and girls with inherited bleeding disorders including von Willebrand disease.
  • Yale UniversitycoreStrategic or Co-development Partner · 24 March 2026Academic collaborator for LUNA Trial women's health clinical study. Partnership with OHSU and University of Michigan funded by Wellcome Leap to advance non-pharmaceutical treatment options for heavy menstrual bleeding.
  • UT Southwestern Medical CentercoreStrategic or Co-development Partner · 16 February 2026Lead organization for $500,000 TRC4 grant clinical trial evaluating tAN for chronic subdural hematomas. Dr. Alex Valadka leading study to develop less invasive treatment for common neurosurgical condition.
  • UTMB (University of Texas Medical Branch)coreStrategic or Co-development Partner · 16 February 2026Collaborating institution for chronic subdural hematomas clinical trial with UT Southwestern. Partnership part of Trauma Research and Combat Casualty Care Collaborative research initiative.
  • OVOemergingChannel Partner/ Reseller/ Distributor · 17 December 2025Menstrual care brand partnership offering OhmBody neurostimulation device through OVO's online store. OVO is a plant-based menstrual care brand expanding distribution for Spark's non-hormonal menstrual wellness device.
  • Menninger CliniccoreStrategic or Co-development Partner · 20 October 2025Clinical research partner for NIH/NIAAA $305,000 grant studying tAN for alcohol withdrawal in patients with Alcohol Use Disorder. Menninger Clinic is conducting the five-day inpatient protocol study evaluating Sparrow Link device safety and efficacy.
  • Baylor College of MedicinecoreStrategic or Co-development Partner · 20 October 2025Academic partner for NIH/NIAAA alcohol withdrawal study. Collaborating with Menninger Clinic to evaluate neural mechanisms of tAN therapy in treating alcohol use disorder.
  • Battelle Memorial InstitutecoreStrategic or Co-development Partner · 12 September 2024Strategic technology partner for AI algorithm development to detect and manage opioid withdrawal symptoms. Funded by $318,875 NIDA SBIR grant. Battelle contributing technical expertise for closed-loop neurostimulation development.
  • Hazelden Betty Ford FoundationcoreStrategic or Co-development Partner · 12 September 2024Clinical partner for AI algorithm development project funded by NIDA. Hazelden Betty Ford Foundation provides addiction treatment expertise and clinical data for algorithm training to detect opioid withdrawal symptoms and cravings.
  • Battelle Memorial InstitutecoreStrategic or Co-development Partner · 14 December 2023Long-standing partner for military neurostimulation device development. $1.15 million DoD Phase II grant for Sparrow Hawk device to address Acute Stress Reactions in military settings. Battelle developing wearable non-invasive device for battlefield conditions.
  • Lindus HealthminorStrategic or Co-development PartnerPartner for decentralized clinical trial operations for HMB/VWD study involving 20 subjects. Lindus Health providing clinical trial management services.
  • Northwell Health / Feinstein InstitutescoreStrategic or Co-development PartnerResearch partner for platelet activity regulation study (NCT05977946). Feinstein Institutes known for vagus nerve stimulation research. Partnership leverages deep expertise in bioelectronic medicine.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Spark Biomedical competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Spark Biomedical social profiles

Digital presence

Spark Biomedical compliance and trust

Trust signal

Compliance2 records

Spark Biomedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Spark Biomedical leadership team

Management profile

Number of profiles

Profiles4 records

Spark Biomedical subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Spark Biomedical funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Spark Biomedical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spark Biomedical

What does Spark Biomedical do?

Spark Biomedical develops and sells FDA-cleared, non-invasive wearable neurostimulation devices based on its proprietary Transcutaneous Auricular Neurostimulation (tAN) technology. The flagship product, Sparrow Ascent, is a wearable ear-piece device that delivers targeted electrical stimulation to the auricular branch of the vagus and trigeminal nerves to manage opioid withdrawal symptoms, with extensions into neonatal withdrawal, military acute stress, hemostasis, and women's menstrual wellness. The company also sells the Sparrow Link research platform to academic and clinical investigators, and operates a direct-to-consumer e-commerce channel at SparrowRx.com.

Is Spark Biomedical a public or private company?

Spark Biomedical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Spark Biomedical founded?

Spark Biomedical was founded in 2017. It employs 11 to 50 people.

Where is Spark Biomedical based?

Spark Biomedical is headquartered in Dallas, United States, in the North America region.

How does Spark Biomedical make money?

Three revenue lines are on record. Sparrow Ascent Device Sales are the primary driver. The others are sparrow Link Research Platform and SEC Exempt Offering.

Does Spark Biomedical have an API?

No public API is recorded for Spark Biomedical.

What industry is Spark Biomedical in?

Spark Biomedical's product category is Wearable Neurostimulation Medical Devices. Its primary akta.pro industry code is HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables), with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSpark Biomedical Expands Leadership Team to Speed CommercializationSpark Biomedical announced the addition of three executives and an elevation of Amy Gaston to VP of Marketing to accelerate commercialization. The new team includes Ric Peterson as CFO, Tom Futch as EVP of Growth, and Jeff Jones as EVP of Manufacturing Operations. They will support multi-channel sales, manufacturing capacity, and financial systems for the company's next growth phase.PR NewswireSpark Biomedical to Present Acute Stress Reaction, Anxiety, and Sleep Data at 2026 Military Health System Research SymposiumSpark Biomedical announced its participation in the 2026 Military Health System Research Symposium, where it will present two scientific posters on applications of its transcutaneous auricular neurostimulation (tAN®) platform for military and first responder use cases.BioSpaceSpark Biomedical to Present Acute Stress Reaction, Anxiety, and Sleep Data at 2026 Military Health System Research SymposiumSpark Biomedical will present two posters at the 2026 Military Health System Research Symposium in Kissimmee, Florida, on August 3–6. The posters examine its tAN platform for reducing stress and improving sleep in military and first responder contexts. The company's presence marks a strategic expansion into the military-ready space.FierceBiotech‘Neural tourniquet’ device could hold key to stopping life-threatening hemorrhageResearchers from Northwell Health's Feinstein Institutes for Medical Research published data in Bioelectronic Medicine showing that electrical stimulation of the ear can boost blood clotting in healthy adults. The study tested Spark Biomedical's transcutaneous auricular neurostimulation platform, finding that both taVNS and combined vagal/trigeminal stimulation approaches successfully activated platelets and accelerated blood clot formation. The device, described as a 'neural tourniquet,' remains early-stage and will require further trials to validate its effectiveness for treating severe bleeding in trauma or battlefield settings.Business Wire BlogFeinstein Institutes Scientists Discover How Bioelectronic Medicine Activates Blood ClottingScientists from Northwell Health's Feinstein Institutes for Medical Research published a first-in-human mechanistic study demonstrating that a small wearable device placed on the ear can activate the vagus nerve through transcutaneous auricular neurostimulation (tAN®) and safely accelerate blood clot formation in healthy adults. The research, conducted using Spark Biomedical's proprietary tAN® platform, showed that both taVNS and combined vagal-trigeminal nerve stimulation successfully activated platelets and accelerated all phases of blood clotting without adverse events. This study advances the development of the "Neural Tourniquet," a bioelectronic therapy intended to leverage the body's nervous system to control life-threatening hemorrhage across clinical scenarios including traumatic injuries, surgical complications, bleeding disorders, and postpartum hemorrhage.BioSpaceFeinstein Institutes Scientists Discover How Bioelectronic Medicine Activates Blood ClottingA first-in-human study from Northwell Health's Feinstein Institutes found that non-invasive ear stimulation activates the vagus nerve and accelerates blood clotting in healthy adults. The study, published in Bioelectronic Medicine, showed both vagus and combined vagus-trigeminal stimulation improved platelet function without adverse events. The findings support the Neural Tourniquet's potential for treating severe bleeding.PR NewswireSpark Biomedical and Feinstein Institutes Publish First-in-Human Study Demonstrating Non-Invasive tAN® Technology Enhances Platelet FunctionSpark Biomedical and Feinstein Institutes published a first-in-human study in Bioelectronic Medicine showing their tAN platform safely enhances platelet function. The wearable ear-based neurostimulation increased platelet activity without systemic effects or adverse events, supporting a new class of non-pharmacologic treatments for severe bleeding.Dallas InnovatesSpark Biomedical Names MedTech Veteran as Its New CEOSpark Biomedical, a Dallas-based wearable neurostimulation company, has appointed Anja Krammer, a medtech veteran with experience scaling healthcare and medical technology companies, as its new CEO effective May 4th. Krammer will focus on accelerating growth by advancing clinical programs, regulatory pathways, commercial capabilities, and strategic partnerships. Outgoing CEO and cofounder Daniel Powell will transition to lead the company's Neural Tourniquet product through FDA approval and commercialization.GlobeNewswireSpark Biomedical Appoints Anja Krammer as Chief Executive Officer to Accelerate Clinical and Commercial GrowthSpark Biomedical, a Dallas-based bioelectronic medicine company, has appointed Anja Krammer as Chief Executive Officer effective May 4, 2026, replacing cofounder Daniel Powell. Krammer brings extensive experience scaling healthcare and medical technology companies across cardiac, dermatology, and women's health markets, with a mandate to accelerate clinical programs, expand commercial capabilities, and drive revenue growth. Outgoing CEO Powell will transition to lead the company's Neural Tourniquet product through FDA approval and commercialization.GlobeNewswireTwo Medtech Industry Leaders Selected to Serve on NIH HEAL Initiative® Multi-Disciplinary Working GroupTwo medical technology industry leaders, Dr. Navid Khodaparast of Spark Biomedical and Dr. Amy Baxter of Harmonic Scientific, have been selected to serve on the NIH HEAL Initiative Multi-Disciplinary Working Group for four-year terms beginning July 2026. The working group provides strategic input on research priorities addressing the nation's opioid epidemic and chronic pain crisis. The selection highlights the growing role of neuromodulation and noninvasive intervention technologies in developing solutions for opioid use disorder and chronic pain management.